• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Neonatal Monkeypox Virus Infection (NEJM, Correspondence, October 12, 2022)

Pathfinder

Editor, Senior Moderator
CORRESPONDENCE


Neonatal Monkeypox Virus Infection


October 12, 2022
DOI: 10.1056/NEJMc2210828
Metrics


TO THE EDITOR:

The ongoing monkeypox outbreak was recently declared to be a Public Health Emergency of International Concern by the World Health Organization.1 Young children are at risk for severe disease; therefore, early recognition and prompt treatment are important.2


Figure 1. Monkeypox Skin Lesions in a Newborn Infant.

Shown are monkeypox skin lesions on the hands and feet of a newborn infant. Visible lesions range from vesicles to pustules, and lesions that were beginning to form scabs are also shown. Photographs were obtained on day 5 after the onset of rash.

nejmc2210828_f1.jpeg


We report a case of perinatally acquired monkeypox virus infection and adenovirus coinfection in a 10-day-old infant. After the infant’s uneventful birth in late April 2022, a rash developed on day 9 of life. The rash was initially vesicular, starting on the palms and soles and subsequently spreading to the face and trunk, and gradually became pustular (Figure 1). Nine days before the birth, the infant’s father had had a febrile illness, followed by a widespread rash; the rash resolved before the infant’s birth. Four days after the infant’s delivery, a similar rash developed in the mother. The family lived in the United Kingdom, and there was no history of travel to Africa or of contact with any travelers.

The infant was transferred to the regional pediatric intensive care unit on day 15 of life owing to evolving hypoxemic respiratory failure (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). A number of diagnoses (neonatal varicella, herpes simplex virus infection, coxsackievirus or enterovirus infection, staphylococcal skin infection, scabies, syphilis, and gonorrhea) were considered. The presence of axillary lymphadenopathy, the nature of the skin lesions, and the atypical timeline of intrafamilial infection aroused concern regarding human monkeypox. Polymerase-chain-reaction testing of blood, urine, vesicular-fluid, and throat-swab samples obtained from the infant and mother led to a diagnosis of monkeypox virus infection (clade IIb). Adenovirus was also identified in the infant’s respiratory secretions and blood. The infant’s condition worsened, and invasive ventilation was initiated. A 2-week course of enteral tecovirimat (at a dose of 50 mg twice a day) was commenced in combination with intravenous cidofovir. After 4 weeks in intensive care, including 14 days of invasive ventilation, the infant recovered and was discharged home. The timeline of intrafamilial infection and test results is shown in Figure S2.

Reports of neonatal monkeypox virus infection are rare.3 This was a case of neonatal monkeypox virus infection after peripartum transmission within a family cluster; transplacental transmission could not be ruled out.4 Because this was a single case, it is not possible to attribute the clinical illness to either pathogen (monkeypox virus or adenovirus) directly, nor is it possible to attribute the improvement in the infant’s clinical condition to the use of tecovirimat or cidofovir.5 Monkeypox virus infection should be considered in the differential diagnosis of a neonatal vesicular rash.

Padmanabhan Ramnarayan, M.D.
Imperial College London, London, United Kingdom
p.ramnarayan@imperial.ac.uk

Rebecca Mitting, M.B., B.S.
Imperial College Healthcare NHS Trust, London, United Kingdom

Elizabeth Whittaker, Ph.D.
Imperial College London, London, United Kingdom

Maria Marcolin, M.R.C.P.C.H.
Ciara O’Regan, M.R.C.P.C.H.
Ruchi Sinha, M.R.C.P.C.H.
Aisleen Bennett, Ph.D.
Moustafa Moustafa, M.R.C.P.C.H.
Neil Tickner, M.Pharm.
Mark Gilchrist, M.Sc.
Imperial College Healthcare NHS Trust, London, United Kingdom

Anthony Kershaw, M.R.C.P.C.H.
London Northwest University Healthcare NHS Trust, London, United Kingdom

Tommy Rampling, D.Phil.
U.K. Health Security Agency, London, United Kingdom

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on October 12, 2022, at NEJM.org.

A list of the members of the NHS England High Consequence Infectious Diseases (Airborne) Network is provided in the Supplementary Appendix, available at NEJM.org.

https://www.nejm.org/doi/full/10.1056/NEJMc2210828?query=featured_home
 
Back
Top